Core Insights - Kenvue Inc. was spun off from Johnson & Johnson in May 2023, aiming to establish itself as a stable entity in the market [1] Company Overview - The spin-off allows Kenvue to operate independently, focusing on its core business without the complexities associated with its parent company [1] Investment Perspective - The investment strategy emphasizes a fundamentals-first approach, highlighting the importance of uncovering mispriced assets that the market may overlook [1]

Core Insights - The article emphasizes the importance of a stock portfolio for investors nearing or in retirement, highlighting the need for a balance of reliable income, low volatility, and consistent dividend growth [1] Investment Strategy - A well-structured stock portfolio should focus on generating dependable income streams, which is crucial for retirees [1] - Low volatility is essential to minimize risks associated with market fluctuations, providing a sense of security for investors [1] - Consistent dividend growth is a key factor in maintaining and enhancing income over time, making it an attractive feature for retirement portfolios [1]

Group 1 - Johnson & Johnson (JNJ) shares rose by 1.7% following a report indicating that Tecvayli combined with Darzalex reduces the risk of disease progression or death by 83% compared to standard treatment options [1][2] - The report suggests that this combination therapy may support earlier line usage as treatment paradigms evolve [1][2] - The collaboration partner for Carvykti, Legend Biotech (LEGN), is also gaining attention in light of these developments [1][2]

Core Insights - Johnson & Johnson (JNJ) and Pfizer (PFE) are both prominent players in the healthcare sector, with extensive drug portfolios and diversified revenue streams, making them direct competitors in the blue-chip healthcare market [1][2] - JNJ has a strong presence in oncology, immunology, neuroscience, cardiovascular and metabolic diseases, pulmonary hypertension, and infectious diseases, while PFE excels in inflammation, immunology, rare diseases, and vaccines [1][2] Summary of J&J - JNJ's diversified business model, which includes pharmaceuticals and medical devices, allows it to better withstand economic fluctuations [3] - In 2025, JNJ's Innovative Medicine unit saw a 3.4% organic sales increase despite the loss of exclusivity for its product Stelara, driven by key drugs like Darzalex, Erleada, and Tremfya, along with new launches [4] - The MedTech segment has shown improvement due to acquisitions in cardiovascular businesses and advancements in electrophysiology [5] - JNJ plans to separate its Orthopaedics franchise into a standalone company, which is expected to enhance growth and margins in its MedTech unit [6] - Sales in China are negatively impacted by the volume-based procurement program, but JNJ anticipates accelerated growth in both Innovative Medicine and MedTech segments in 2026 [7] - JNJ has made significant progress in its pipeline, gaining approvals for new products that could drive growth through the latter half of the decade [8] - JNJ estimates that 10 of its new products have the potential to achieve peak sales of $5 billion [9] Summary of Pfizer - PFE is a leading drugmaker in oncology, with oncology sales accounting for approximately 28% of its total revenue, which has increased by 7% year-to-date [11] - Non-COVID operational revenues are improving, supported by key products and new launches, with a projected revenue CAGR of about 6% from 2025 to 2030 [12][13] - PFE has invested significantly in business development, including a $10 billion acquisition to re-enter the obesity market, which is expected to generate substantial peak sales [14] - A recent drug pricing agreement with the U.S. government provides clarity on PFE's strategic investments [15] - PFE faces challenges, including declining sales of COVID products and significant impacts from upcoming patent expirations [16][17] Financial Estimates - The Zacks Consensus Estimate for JNJ's 2025 sales and EPS indicates a year-over-year increase of 5.5% and 8.9%, respectively [18] - In contrast, PFE's 2025 sales are expected to decline by 1.08%, although earnings are projected to increase by around 1% [18] - JNJ's stock has risen 38.3% year-to-date, while PFE's stock has declined by 4.5% [22] - JNJ's dividend yield is 2.6%, compared to PFE's 6.8% [28] Investment Comparison - JNJ's improving growth prospects and rising estimates suggest it may be a better investment option compared to PFE, which has faced revenue declines due to lower sales of COVID products [31][33] - Despite challenges, JNJ's consistent revenue and EPS growth, along with strong cash flows and a long history of dividend increases, position it favorably [31][32]

Core Insights - The healthcare sector has significantly outperformed the broader market, with the S&P 500 Health Care Sector index rising approximately 5.1% over the past month compared to a 2.3% increase in the S&P 500 index, primarily driven by blockbuster drugs [1] Company Highlights - Eli Lilly's GLP-1 medication, tirzepatide, became the best-selling drug globally in the third quarter, contributing to a 9.1% increase in its stock price over the past month [3] - Eli Lilly's current market capitalization stands at $943 billion, with a stock price range between $993.00 and $1011.00 [4] - Johnson & Johnson announced the acquisition of Halda Therapeutics, a company focused on developing oral therapies for solid tumors, leading to an 8.6% increase in its stock price over the past month [5] - AbbVie's Skyrizi and Rinvoq saw substantial sales growth, with Skyrizi sales rising 46.8% to $4.7 billion and Rinvoq sales increasing 35.3% to nearly $2.2 billion in the third quarter, contributing to a 4.3% rise in its stock price [6] - Merck's Keytruda achieved quarterly sales exceeding $8 billion for the first time, resulting in an 18.2% increase in its stock price over the past month [7]

Core Insights - Dividend investors often focus on well-known companies like Pepsi, Johnson & Johnson, and Procter & Gamble, but this approach overlooks numerous other opportunities that may offer better returns [1][2] - There are lesser-known dividend stocks that operate in stable industries, consistently raise their payouts, and outperform larger, more popular dividend stocks [2][4] - The current market volatility has prompted investors to seek companies that can grow without relying on ideal market conditions, making these under-the-radar dividend stocks appealing for their stability and potential upside [4][5] Company Summaries - **Rexford Industrial Realty**: Operates industrial properties in Southern California, the largest supply-constrained industrial market in the U.S. The company has achieved a compound growth rate of 16% in funds from operations over the past five years, nearly double that of its peers. The stock yields 4.21%, with an annual return of $1.72 per share, and has increased dividends for 12 consecutive years [8][9] - **Automatic Data Processing (ADP)**: Known for payroll and HR services, ADP has raised its dividends for 51 years. The stock yields 2.60% with an annual dividend of $6.80. The company maintains a moderate payout ratio, indicating potential for future increases, and benefits from predictable cash flow due to high client retention [11][12][13] - **Williams Sonoma**: A well-known retail name that has successfully navigated supply chain challenges and changing consumer habits. The company has a consistent dividend growth supported by strong operating cash flow. The stock yields 1.49% with an annual dividend of $2.64 and a payout ratio of 27.98%, making it an attractive option for investors [15][16]

Core Insights - The combination of TECVAYLI and DARZALEX FASPRO shows a statistically significant improvement in progression-free survival and overall survival for patients with relapsed/refractory multiple myeloma compared to standard treatments after three years of follow-up [1][4] - The combination has received Breakthrough Therapy Designation from the U.S. FDA, indicating its potential to significantly improve treatment outcomes for serious conditions [1][8] Study Results - The Phase 3 MajesTEC-3 study demonstrated an 83% reduction in the risk of disease progression or death with a hazard ratio of 0.17, and 91% of patients who were progression-free at six months remained so at three years [1][2] - Key secondary endpoints showed significant improvements, including complete response rates of 81.8% versus 32.1% for standard care, and overall response rates of 89.0% versus 75.3% [4] - Overall survival rates at three years were 83.3% for the combination therapy compared to 65.0% for standard care [4] Safety Profile - The combination therapy exhibited similar rates of Grade 3/4 treatment-emergent adverse events compared to standard care, with most events related to cytopenia and infections [6][7] - Cytokine release syndrome occurred in 60.1% of patients, but all cases were Grade 1/2 and managed effectively [7] - Serious adverse events were reported in 70.7% of patients receiving the combination therapy, with low treatment discontinuation rates due to adverse events [7] Regulatory and Market Implications - Johnson & Johnson is actively working with global regulatory bodies to expedite the availability of this combination therapy for eligible patients, having submitted a supplemental Biologics License Application to the FDA [8][9] - The FDA's Breakthrough Therapy Designation aims to accelerate the development and review process for this promising treatment [8] Future Outlook - The combination of TECVAYLI and DARZALEX FASPRO is positioned to potentially redefine the standard of care for multiple myeloma, with ongoing exploration of its use in various treatment regimens [5][10] - The MajesTEC-3 study is part of a broader clinical program aimed at enhancing treatment options for patients with multiple myeloma [10]

Core Viewpoint - The article emphasizes that despite the narrative of declining American manufacturing, the U.S. remains a leading manufacturing power globally, significantly outpacing Europe and Japan, particularly in high-end manufacturing sectors [2]. Group 1: Major Manufacturing Giants - Lockheed Martin is the largest defense contractor in the U.S., consistently topping Pentagon procurement lists with products like the F-22 and F-35 fighter jets, and the Perseverance Mars rover [4]. - General Electric (GE), founded by inventor Thomas Edison, is a leader in aviation engines, with the CFM56 engine being one of the most successful in aviation history, and the LEAP engine dominating orders for Airbus A320 and Boeing 737 [6]. - Caterpillar is the world's largest manufacturer of construction machinery, known for its advanced diesel engine technology and the 797F mining truck, which can carry 400 tons of ore [8]. - 3M is the largest manufacturer of specialty materials, with its iconic transparent tape and a wide range of products used across various industries [10]. - Boeing is the largest aerospace manufacturer globally and the second-largest defense contractor in the U.S., producing a range of military and commercial aircraft [11]. - Johnson & Johnson is the highest revenue and market cap healthcare company, with innovative products contributing significantly to its income, including a projected $56.9 billion from its pharmaceutical segment in 2024 [13]. - Honeywell provides essential technology for aircraft, including flight management systems and is one of the few manufacturers of black boxes [15]. - Apple commands 19% of the global smartphone market but captures 80% of the industry's profits, leading in innovation with products like the iPhone and Apple Watch [17]. - NVIDIA, despite a recent stock price drop, remains the highest-valued company globally, with a market cap exceeding $4.3 trillion, and continues to dominate the AI chip market [19]. - ExxonMobil, with a history dating back to 1870, is one of the largest oil companies globally, with projected revenues of $350 billion in 2024 [21]. Group 2: Manufacturing's Economic Impact - Over 60% of the U.S. service industry supports manufacturing, indicating that the contribution of manufacturing to GDP exceeds 60%, reinforcing the U.S.'s status as a manufacturing powerhouse [21]. - The U.S. has been advocating for the return of manufacturing to reduce dependency on Chinese supply chains, highlighting the importance of recognizing this reality in the context of international competition [21].

Core Insights - The article discusses the trends in the development of autoimmune disease treatments, highlighting the significant growth in the global autoimmune drug market, which reached $156 billion in 2023 with a compound annual growth rate of 15% [1][2]. Group 1: Market Overview - The success of TNFα inhibitors and the emergence of IL inhibitors have marked a new era in treatment innovation [1]. - Leading products like Humira and Stelara are facing competition from biosimilars, while others like Dupixent and Skyrizi have set high efficacy standards in their respective indications [1][3]. - The market is expected to continue growing over the next three to five years, driven by the launch of JAK inhibitors and IL inhibitors across multiple disease areas [1][3]. Group 2: Competitive Landscape - Nine companies have six or more marketed products and pipeline drugs, indicating intense competition for leadership in the immunology field [3][4]. - The market is currently dominated by multi-indication blockbuster drugs, with significant ongoing clinical trials aimed at expanding indications for existing products [9][10]. Group 3: Innovation and Development Trends - Companies are increasingly focusing on new molecular entities (NMEs) and innovative treatment strategies, with 70% of pipelines dedicated to novel drug development [9][13]. - The emergence of Chinese pharmaceutical and biotech companies is notable, with firms like 3SBio and Jiangsu Hengrui actively researching innovative targets and NMEs [13][16]. - The industry is shifting towards more precise therapies, progressive innovations, and complex combination dynamics, with a focus on improving patient adherence and treatment convenience [18][23]. Group 4: Future Directions - The article emphasizes the importance of biomarker-driven patient stratification and the expansion of multi-indication models as foundational strategies in autoimmune drug development [21][22]. - The trend of "test and learn" is gaining traction, leading to increased trial activities in rare indications [21][23]. - The industry is also moving towards combination therapies and innovative drug delivery methods, such as oral formulations, to enhance patient convenience and treatment outcomes [24].

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 44 Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time. The audio webcast replay will be available approximately 48 hours after the webcast. thth A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be ava ...